SANUWAVE Health (OTCMKTS:SNWV) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Earnings & Valuation
This table compares SANUWAVE Health and iCAD’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SANUWAVE Health||$1.85 million||12.75||-$11.63 million||($0.08)||-1.56|
|iCAD||$25.62 million||5.07||-$9.02 million||($0.38)||-17.74|
Risk and Volatility
SANUWAVE Health has a beta of -1.56, indicating that its share price is 256% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.
Insider and Institutional Ownership
0.4% of SANUWAVE Health shares are held by institutional investors. Comparatively, 19.0% of iCAD shares are held by institutional investors. 23.4% of SANUWAVE Health shares are held by company insiders. Comparatively, 10.1% of iCAD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares SANUWAVE Health and iCAD’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for SANUWAVE Health and iCAD, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
iCAD beats SANUWAVE Health on 6 of the 10 factors compared between the two stocks.
About SANUWAVE Health
SANUWAVE Health, Inc., a shock wave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications worldwide. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead product candidate is the dermaPACE device, which has completed its initial Phase III, IDE clinical trial for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. It markets and sells its devices and accessories. SANUWAVE Health, Inc. was founded in 2005 and is headquartered in Suwanee, Georgia.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Receive News & Ratings for SANUWAVE Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SANUWAVE Health and related companies with MarketBeat.com's FREE daily email newsletter.